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there is mounting evidence that hypoxia 
modulates immune and inflammatory 
responses, the role of hypoxic signal-
ing in renal immune-mediated injury is 
largely unexplored. Rama and colleagues1 
propose that hypoxia is a key regulator of 
DC maturation in the kidney, suggest-
ing a novel mechanism by which oxygen 
regulates immune responses. Their work 
will stimulate future investigations into 
the role of molecular oxygen sensing in 
immune-cell maturation and function 
and has implications for acute and chronic 
renal injuries in the transplantation and 
non-transplantation settings.
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Hepatitis B in chronic kidney 
disease: Moving toward effective 
prevention
JK Unger1 and H Peters2
Control of hepatitis B virus (HBV) infection has been a continuous 
challenge in the management of patients with advanced kidney 
disease. HBV infections are still difficult to treat, so the main objective 
is disease prevention by timely immunization with hepatitis B surface 
antigen vaccines. In the general population, a simple two- or three-
standard-dose vaccination strategy has been proven to be highly 
successful. In contrast, an intensified and more tailored approach is 
evolving in patients with advanced renal failure.
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Infection and spread of hepatitis B virus 
(HBV) are a medical problem with glo-
bal dimension. More than 2 billion 
people are estimated to be infected 
with HBV worldwide, 360 million have 
chronic infection, and 600,000 die each 
year from HBV-related acute hepatitis, 
liver fibrosis, or hepatocellular car-
cinoma.1 HBV belongs to a family of 
hepadnavirus, consists of seven major 
genotypes (A to G), and is relatively 
small (approximately 45 nm in diam-
eter). Humans are the only natural host 
known, and virus transmission occurs 
primarily via direct blood or mucous 
membrane contact. The major envelope 
protein of HBV is the hepatitis B surface 
antigen (HBsAG). HBsAG was the ﬁrst 
identiﬁed blood marker for active HBV 
infection and was originally called ‘Aus-
tralia antigen.’1,2 HBsAG has become 
the main pathogen used for HBV vac-
cines. In the beginning, HBsAG vaccine 
was derived from plasma of infectious 
patients, but this has been replaced 
subsequently by recombinant vaccines 
produced in yeast.
Over the past 20 years, HBV vaccina-
tion has become one of the most eﬀective 
single medical interventions in the con-
trol of infectious disease. Rates of sero-
protection up to 95% have been achieved 
with a relatively simple two- or three-
standard-dose vaccination strategy.1,2 
Today’s HBV standard vaccine consists of 
20 µg HBsAG in conjunction with 0.5 mg 
aluminum salt as adjuvant. In the general 
population, seroprotection is deﬁned by 
an HBsAG antibody titer greater than 
10 mIU/ml. The HBV vaccine has been 
proven to be very safe, and there is no 
convincing evidence for any long-term 
undesirable sequel. As part of a global ini-
tiative, many countries have implemented 
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routine HBV vaccination schedules for 
newborns and infants. This initiative 
has already yielded pediatric HBV vac-
cination rates of over 50% worldwide in 
recent years.3 Thus, global eradication 
of HBV infection may become a distinct 
possibility for future generations.
Aside from the global dimension, 
infection and spread of HBV have been 
ongoing challenges in the very special 
microenvironment of dialysis units 
since the beginning of chronic dialysis 
programs in the late 1960s.4,5 The early 
times were characterized by high preva-
lence of HBsAG-positive dialysis patients 
and staﬀ members and by local hepatitis 
epidemics. To date, HBV in dialysis units 
has been a problem, with continuous and 
still ongoing improvement in its man-
agement. Throughout the past 50 years, 
major advances have been achieved by 
increasingly more sophisticated routine 
serological screening methods for HBV 
infection, guidelines for hygiene pre-
cautions, segregation of infectious and 
noninfectious patients in dialysis units, 
HBV testing of blood transfusions, intro-
duction of erythropoietin to avoid blood 
transfusions, and, beginning in the 1980s, 
introduction of routine HBV vaccination 
of dialysis patients and staﬀ.4–6 Conse-
quently, the number of HBV infections 
has declined, but even today the HBV 
incidence in hemodialysis units is still 
unacceptably high and far away from 
adequate control. It is estimated that 
up to 4% of hemodialysis patients are 
chronically infected with HBV in North 
America, Western Europe, and Japan.4–7 
In less developed countries, single-center 
reports indicate prevalence rates up to 
the range of 10%–20%.7 This substantial 
diﬀerence reﬂects mainly the geographi-
cal distribution of the virus throughout 
the world, but also the smaller resources 
available to prevent HBV infection in 
these areas.
A major cause of the unsatisfactory 
HBV control in chronic dialysis programs 
has been the insuﬃcient response to HBV 
vaccination in patients with end-stage 
renal disease.4,5 Following HBV standard 
vaccination schedules, rates of seroprotec-
tion and anti-HBsAG peak titers and anti-
body persistence are substantially lower 
in hemodialysis patients, thus precluding 
suﬃcient prevention in this vulnerable 
population. Some, but still not adequate, 
improvement is yielded when the HBsAG 
vaccine is administered in double stand-
ard dose with an intensiﬁed time schedule 
(40 µg HBsAg at 0, 1, 2, and 6 months) as 
actually recommended by the Centers for 
Disease Control and Prevention.6 Other, 
multifold attempts to enhance HBV vac-
cination in dialysis patients have been 
mainly ineﬀective. These have included 
intradermal application and coadmin-
istration of immune-modulating agents 
such as granulocyte–macrophage colony-
stimulating factor, interferon-γ, zinc, 
levamisole, and interleukin-2.4,5
In both predialysis and dialysis 
patients, the insufficient response to 
HBV vaccine is largely the result of a 
general immune-compromised state 
that is characteristic of advanced renal 
failure.4,5,7 Further negatively modu-
lating factors that have been identiﬁed 
are diabetes mellitus, older age, mal-
nutrition, erythropoietin deficiency, 
ineffective dialysis, and chronic bio-
incompatibility of the hemodialysis 
procedure. One key feature of uremic 
immune system suppression is a mark-
edly diminished activation of ‘memory’ 
in immune-competent cells following 
antigen stimuli.4,5,8 This makes dialy-
sis patients much more dependent on 
circulating antibodies in case of patho-
gen exposure. With regard to HBV vac-
cination, it is currently recommended 
to maintain anti-HBsAG antibody 
titers above 100 mIU/ml (ten times 
higher than in the normal population) 
to achieve adequate seroprotection in 
hemodialysis patients.8
Kong et al.8 (this issue) report on a 
novel adjuvant system, AS04, that greatly 
enhanced the long-term antibody response 
to HBsAG vaccine in a cohort of patients 
with advanced renal failure, that is, predi-
alysis and dialysis patients. In a randomized 
international multicenter study design, the 
actual recommended vaccination standard 
(40 µg HBsAG with standard 0.5 mg alumi-
num adjuvant at 0, 1, 2, and 6 months) was 
compared with 20 µg HBsAG with AS04 
Figure 1 | Model of hepatitis B surface antigen vaccination. At minimum, the vaccine must 
consist of the hepatitis B surface antigen (HBsAG) antigen and an adjuvant, in this case AS04 
aluminum salt and the highly immunogenic monophosphoryl lipid A (MPL).8 MPL adjuvant is 
considered to stimulate the innate immune response on dendritic cells, potentially through Toll-
like receptor-4 or other, not-yet-defined common pathogen-recognition pathways.9,10 This leads to 
an antigen-specific costimulatory signal on T cells. The specific adaptive immune response — that 
is, antibodies to HBsAG — is elected after B cells are stimulated by both the specific antigen (signal 
1) and the specific costimulatory T-cell signal (signal 2).
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adjuvant given on an identical time sched-
ule. Information on potentially modifying 
underlying renal and concomitant diseases 
is not provided. After 42 months of follow-
up, the AS04-based HBsAG vaccine elic-
ited signiﬁcantly greater immunogenicity 
(immune response following antigen 
exposure), as shown by the higher rate of 
patients having anti-HBsAG titers higher 
than 10 mIU/ml (78% versus 51%) and 
100 mIU/ml (54% versus 29%) and fewer 
patients requiring booster doses (43% ver-
sus 17%).8 Furthermore, a booster dose 
with HBV-AS04 was shown to be highly 
eﬀective when given to all patients remain-
ing after 42 months irrespective of their 
previous vaccination group. Reactogenicity 
(adverse events following vaccination), on 
the other hand, was increased as well with 
the novel AS04 vaccine but remained in an 
acceptable range.8
The report by Kong et al.8 reveals that in 
addition to dose and number of pathogen 
inoculation, the coadministered adjuvant 
can be much more critical for enhanced 
vaccine immunogenicity than previously 
expected. The AS04 adjuvant utilized 
monophosphoryl lipid A, a derivative of 
the active moiety of bacterial lipopoly-
saccharide.9 Monophosphoryl lipid A is 
thought to act as an agonist on Toll-like 
receptor-4 and thereby links the innate 
immune system to the adaptive immune 
response, that is, antibody production by 
B cells.9,10 Figure 1 provides a schematic 
model showing how vaccine pathogen and 
adjuvant may interact with endogenous 
immune cells to produce immunogenicity. 
Further, even more promising new vac-
cine adjuvants, such as small oligodeoxy-
nucleotide ligands to Toll-like receptor-9, 
are already in clinical testing.9,10 Whether 
these new vaccine adjuvants may act as 
well through other innate pathogen-rec-
ognition receptors or even other pathways 
is currently debated.9,10
In conclusion, prevention of hepatitis 
B infection and disease in patients with 
advanced or end-stage renal disease has 
largely improved over the recent decades. 
HBsAG vaccination dose, adjuvant, and 
time schedule have been adapted, intensi-
ﬁed, and tailored for this population. How-
ever, there is still a substantial gap to close 
for suﬃcient prevention of HBV infection 
and disease. Until more eﬀective vaccines 
are available, we feel that HBV vaccination 
should be considered even at early stages of 
chronic kidney disease (CKD) and imple-
mented as a standard routine vaccination 
starting in patients at CKD stage 3. HBV 
vaccination is safe and eﬀective and has 
become an integral part of many stand-
ard immunization programs worldwide. 
CKD stage 3 patients are clearly at risk for 
becoming dialysis-dependent and in most 
cases are not yet immune-compromised. 
Implementation of HBV vaccination strat-
egy as early as CKD stage 3 would mark-
edly bolster our attempts to prevent HBV 
infection and disease in patients with more 
advanced or end-stage renal failure.
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Acute kidney injury: Better 
biomarkers and beyond
CR Parikh1 and AX Garg2
We review fundamental epidemiologic concepts for testing the new 
early acute kidney injury biomarkers in clinical care.
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Acute kidney injury (AKI) has a strong 
impact on morbidity, mortality, and 
resource utilization regardless of the 
etiology, setting, or definition used. 
Unfortunately, there are virtually no 
therapies to reverse AKI. Those applied 
late in the course of the injury, after an 
obvious increase in serum creatinine, 
have proven ineffective. Thus, recent 
efforts have focused on the identifi-
cation of early-detection markers of 
AKI, at a critical time when the con-
dition may be responsive to interven-
tion. Over 20 unique serum and urine 
biomarkers have now been reported in 
the past 7 years,1 fueled by advances 
in biotechnology and bioinformatics. 
Han et al.2 (this issue) describe three 
urinary biomarkers: kidney injury 
molecule-1, N-acetyl-β-d-glucosami-
nidase, and matrix metalloproteinase-9. 
Will these promising biomarkers trans-
late into widespread clinical use like car-
diac troponin? Or will they prove less 
than ideal when evaluated in broader 
testing, as in other clinical settings?3,4 
What fundamental epidemiologic con-
cepts need to be considered within a 
